Article

Parasite Remedy Doesn't Change Course of Chagas Damage

Author(s):

Drug kills parasites but too late to prevent heart myopathy in Chagas Disease.

Chagas disease patients who got trypanocidal therapy with benznidazole had relief from the acute phase of the heart illness, but their cardiomyopathy continued to progress, a multi-national study in South America and Latin America found.

According to the US Centers for Disease Control and Prevention, the disease is caused by the parasite Trypanosoma cruzi, which is carried by insects and transmitted to people and animals by bug bites and is common in rural areas of Latin America. Globally it is the third most common parasitic disease.

Carlos Morilla, MD, and colleagues at Population Health Research Institute—Hamilton Health Sciences and McMaster University in Ontario, Canada studied 2,854 patients with heart failure due to Chagas.

They were randomized to benznidazole or placebo and followed for five years.

The drug did kill the parasite in about 2/3 of the patients, but there were no significant clinical cardiac benefits seen.

The study, first published in the New England Journal of Medicine, was highlighted Oct. 27 in JAMA.

Researcher hypothesized that different genetic subtypes of the parasite might be in different patients, possibly explaining why a third of the patients did not see a reduction of circulating parasites in their serum. .

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.